Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

• Published in: Prostate international Vol. 9; no. 2; pp. 96 - 100
• Main Authors: Matsumoto, Takashi, Shiota, Masaki, Nakamura, Motonobu, Yokomizo, Akira, Tomoda, Toshihisa, Sakamoto, Naotaka, Seki, Narihito, Hasegawa, Shuji, Yunoki, Takakazu, Harano, Masahiko, Kuroiwa, Kentaro, Eto, Masatoshi
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.06.2021; Asian Pacific Prostate Society; Elsevier
• Subjects: Cabazitaxel; Castration-resistant prostate cancer; Efficacy; Safety; The elderly; Castration-resistant prostate cancer; Efficacy; Safety; Cabazitaxel; The elderly
• ISSN: 2287-8882; 2287-903X
• DOI: 10.1016/j.prnil.2020.12.001

There is little data on the outcome of cabazitaxel (CBZ) treatment of elderly patients with castration-resistant prostate cancer (CRPC). This study assessed the efficacy and safety of CBZ chemotherapy in patients with CRPC aged 75 years or older in a multiinstitutional study. We retrospectively reviewed the 74 patients with CRPC treated with CBZ enrolled in 10 institutions. Clinicopathological backgrounds, prognosis including prostate-specific antigen decline, time to treatment failure, progression-free survival, overall survival, and safety profiles were compared between younger (<75 years) and elder (≥75 years) patients. In total, 74 patients were enrolled; 50 patients were younger than 75 years and 24 were ≥75 years. Clinicopathological characteristics were comparable between younger and elder patients, with the exception of serum albumin values at the time of CBZ treatment. The median prostate-specific antigen decline in younger and elder men was −8.8% and −32.3% from baseline, respectively. The median time to treatment failure, progression-free survival, and overall survival for younger and elder men were 0.24 and 0.33 years, 0.23 and 0.43 years, and 0.69 and 1.17 years, respectively. In addition, safety profiles were comparable between younger and elder patients. This multiinstitutional study suggests that patients with CRPC aged 75 years or older eligible for CBZ treatment can be treated safely and with noninferior efficacy compared with those younger than 75 years.